Authors
Xinming Jia, Menglu Yu, Dongang Shen, Hongyang Fu, Yuqing Wang, Xiao Wang, Jiaoyan Huang, Shilin Sun, Zhiguo Yu, Yuping Chen, Yunli Zhao
Published in
Frontiers in nutrition. Volume 13. Pages 1855150. Epub Oct 05, 2026.
Abstract
Hyperlipidemia is a widespread metabolic disorder that places a heavy burden on normal body functions. Given the drawbacks of current lipid-lowering drugs, there is considerable interest in developing alternative nutraceuticals from natural sources. S-2-(2-hydroxypropanamido) benzoic acid (S-HPABA) is a novel compound obtained for the first time from a marine fungus, which has demonstrated strong lipid-lowering effects in vitro and in vivo with an excellent safety profile.
To investigate S-HPABA's mechanism of action, an integrated strategy of lipidomics and bioinformatics was adopted to screen candidate targets. The selected targets were then validated through RT-qPCR and western blotting.
The results indicated that 57 differential metabolites and 11 metabolic pathways were significantly regulated by S-HPABA. Based on the combined analyses, five targets were initially selected. Validation experiments showed that FASN, PLA2G2A and TYMP play crucial roles in the lipid-lowering process, with FASN being the most prominent.
Mechanistically, S-HPABA-induced reduction of lipid accumulation was associated with decreased FASN expression and PI3K/AKT/mTOR pathway inhibition. In summary, S-HPABA is a safe and potent lipid-lowering bioactive compound with promise as a functional food ingredient for metabolic health.
PMID:
42898125
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0